Debiopharm

Nuclei's technology, rooted in tissue imaging, will be used to search for biomarkers that predict patients' responses to one of Debiopharm's agents.

The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.

Caris will use its whole-transcriptome sequencing assay and Molecular Intelligence Trials service to identify patients for a phase II clinical trial.